Anthem Biosciences Ltd (ANTHEM)
₹769.90
Mkt cap
₹43,360 Cr
P/E ratio
73.10
P/B
14.20
Div yield
0.26%
ROE
22.30%
ROCE
30.40%
EPS (TTM)
₹10.53
Book value
₹54
52W range
588–865
Sector
Healthcare
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients. [1]
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−10.94% from high₹770
₹588+30.97% from low₹865
Current
₹769.90
Prev close
₹769.10
Day
+0.10%
Price performance
1D
+0.10%
1W
−2.74%
1M
+1.08%
3M
+4.10%
6M
+28.33%
1Y
—
YTD
+17.64%
Financials
FRevenue, profit & margin
P/E ratio
73.1×
ANTHEM is 52% above the sector median of 48.0×
ANTHEM73.1×
Sector median48.0×
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 | |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 | |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 | |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% | |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 | |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 | |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 | |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 | |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% | |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 | |
| EPS in Rs | 1.47 | 2.90 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +2.58% · closed higher next day 2 of last 5
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 2 Per Share | 2.00 | 25 Jun '26 | 26 Jun '26 |
Shareholding
Sas of Jun 202671.42%Promoter
Promoters71.42%3.25
FIIs2.57%1.29
DIIs13.48%1.93
Public12.52%0.04
Ownership trend
Peers
P6 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Anthem Bioscienc | ₹769.90 | 73.08 | 43,360 | 0.26% | 120 | −11.67% | 418 | −22.58% | 30.37% |
| Advanced Enzyme | ₹317.35 | 22.92 | 3,554 | 1.69% | 45 | +61.91% | 203 | +21.65% | 13.96% |
| CCME Global | ₹117.90 | — | 534 | 0.00% | −1 | −2,400.00% | 0 | — | −2.92% |
| Vivo Bio Tech | ₹22.96 | — | 51 | 0.00% | 0 | −85.82% | 14 | +14.15% | 7.29% |
| Shree Ganesh Bio | ₹0.56 | 58.74 | 22 | 0.00% | 0 | +84.21% | 2 | −29.57% | 0.80% |
| Genomic Valley | ₹28.25 | 287.67 | 9 | 0.00% | 0 | +87.50% | 0 | −84.62% | 1.02% |
| Median: 3 Co. | ₹317.35 | 48.00 | 3,554 | 0.26% | 45 | −11.67% | 203 | −0.46% | 13.96% |
Filings
DAnnual reports1
Concall transcripts15
Credit ratings2
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 11hAnnouncement Under 2d - 20th AGM held July 22, 2026; shareholders approved dividend, auditor appointment, and other resolutions.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 2d - Audio recording of Q1 FY2027 earnings call held July 22, 2026, posted on website.Announcement under Regulation 30 (LODR)-Newspaper Publication 2d - Newspaper Publication on Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 21 Jul - Revised Q1FY27 press release shows revenue ₹4,182 Mn, EBITDA ₹1,755 Mn, PAT ₹1,199 Mn.